Nova Patents
ES2525762T5

Composition of antibodies with high ADCC

Abstract

Composition comprising a monoclonal antibody, characterized in that the antibody has in its Fcγ glycosylation site (Asn 297) some glycan structures selected from among the forms:**Formula** in which the content in forms G0+G1+G0F +G1F is greater than 60% and the content in G0F+G1F forms is less than 50%.

Term

Term ended

Projected expiry passed 12 April 2021, 5.5 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

89 members in 11 offices

This recordMember, by publication datePriority claim1 more office is in the list below

Priority claims5

Priority claims
DocumentOfficeKindDate
0004685FranceA
0004685FranceA
0004685France–
0004685–––
FR20000004685–––

Members89

Family members, oldest first
DocumentOfficeKind
US934812AUnited States of AmericaA
US939085AUnited States of AmericaA
US960637AUnited States of AmericaA
CA2406033A1CanadaA1
WO0177181A2World Intellectual Property Organization (WIPO)A2
FR2807767A1FranceA1
AU2001254858B2AustraliaB2
AU5485801AAustraliaA
WO0177181A3World Intellectual Property Organization (WIPO)A3
EP1272527A2European Patent Office (EPO)A2
US2003175969A1United States of AmericaA1
JP2003534781AJapanA
FR2807767B1FranceB1
EP1518864A2European Patent Office (EPO)A2
US2005249722A1United States of AmericaA1
US2007009522A1United States of AmericaA1
AU2007202060A1AustraliaA1
EP1272527B1European Patent Office (EPO)B1
AT419276TAustriaT
ATE419276T2AustriaT2
DE60137210D1GermanyD1
DK1272527T3DenmarkT3
ES2320412T3SpainT3
US7541029B2United States of AmericaB2
EP1518864A3European Patent Office (EPO)A3
US7579170B2United States of AmericaB2
AU2007202060B2AustraliaB2
AU2010257417A1AustraliaA1
US2011052571A1United States of AmericaA1
US2011059072A1United States of AmericaA1
US2011059073A1United States of AmericaA1
US7931895B2United States of AmericaB2
EP2341078A2European Patent Office (EPO)A2
US2011223658A1United States of AmericaA1
EP2341078A3European Patent Office (EPO)A3
US8124078B2United States of AmericaB2
AU2010257417B2AustraliaB2
US8153124B2United States of AmericaB2
US8178093B2United States of AmericaB2
AU2012203957A1AustraliaA1
JP2012191938AJapanA
JP2012193184AJapanA
JP2012193185AJapanA
US2012258096A1United States of AmericaA1
US2012259095A1United States of AmericaA1
US8357370B2United States of AmericaB2
US8409572B2United States of AmericaB2
JP5192625B2JapanB2
JP2013155198AJapanA
US8685725B2United States of AmericaB2
AU2012203957B2AustraliaB2
CA2406033CCanadaC
US2014162356A1United States of AmericaA1
AU2014208242A1AustraliaA1
EP1518864B1European Patent Office (EPO)B1
ES2525762T3SpainT3
DK1518864T3DenmarkT3
JP5722278B2JapanB2
JP5722279B2JapanB2
US2015152189A1United States of AmericaA1
US2015266972A1United States of AmericaA1
JP5788432B2JapanB2
EP2947099A1European Patent Office (EPO)A1
JP2015211696AJapanA
JP2015221827AJapanA
JP5837859B2JapanB2
AU2014208242B2AustraliaB2
AU2016204535A1AustraliaA1
EP2341078B1European Patent Office (EPO)B1
AU2016204535B2AustraliaB2
DK2341078T3DenmarkT3
JP2017012199AJapanA
AU2017200299A1AustraliaA1
ES2601241T3SpainT3
AU2016204535C1AustraliaC1
JP6124958B2JapanB2
US9708409B2United States of AmericaB2
US9718889B2United States of AmericaB2
US9718890B2United States of AmericaB2
AU2017200299B2AustraliaB2
JP2017214427AJapanA
US2018002442A1United States of AmericaA1
EP1272527B2European Patent Office (EPO)B2
US10081683B2United States of AmericaB2
DK1272527T4DenmarkT4
ES2320412T5SpainT5
EP1518864B2European Patent Office (EPO)B2
DK1518864T4DenmarkT4
ES2525762T5This recordSpainT5